I agree that this site is using cookies. You can find further informations here.
X
Quan, Dianna
51  results:
Search for persons X
?
1

Impact of Baseline Neuropathy Severity on Vutrisiran Treatm..:

Luigetti, Marco ; Quan, Dianna ; Berk, John L....
Neurology and Therapy.  13 (2024)  3 - p. 625-639 , 2024
Link: https://doi.org/10.1007/..
 
?
2

Impact de la sévérité de la polyneuropathie à baseline sur ..:

Luigetti, Marco ; Quan, Dianna ; Berk, John L....
Revue Neurologique.  180 (2024)  - p. S116-S117 , 2024
Link: https://doi.org/10.1016/..
 
?
3

Update on Amyloid Polyneuropathy and Treatment:

Živković, Sasha A. ; Avila, J. David ; Gallegos-Kattan, Cesia.
Current Treatment Options in Neurology.  26 (2024)  3 - p. 51-66 , 2024
Link: https://doi.org/10.1007/..
 
?
4

Safety and Efficacy of Nipocalimab in Patients With General..:

Antozzi, Carlo ; Guptill, Jeffrey ; Bril, Vera...
Neurology.  102 (2024)  2 - p. , 2024
Link: https://doi.org/10.1212/..
 
?
5

Hospital admissions among people with diabetes: A systemati..:

Feleke, Berhanu Elfu ; Sacre, Julian ; Tomic, Dunya...
Diabetic Medicine.  41 (2023)  1 - p. , 2023
Link: https://doi.org/10.1111/..
 
?
6

Practical Guidance for the Use of Patisiran in the Manageme..:

Dixon, Stacy ; Kang, Xuan ; Quan, Dianna
Therapeutics and Clinical Risk Management.  19 (2023)  - p. 973-981 , 2023
Link: https://doi.org/10.2147/..
 
?
7

Practical Guidance for the Use of Patisiran in the Manageme..:

Dixon, Stacy ; Kang, Xuan ; Quan, Dianna
info:eu-repo/semantics/altIdentifier/doi/10.2147/TCRM.S361706.  , 2023
Link: https://www.dovepress.co..
 
?
8

Treatment gaps, 1-year readmission and mortality following ..:

Morton, Jedidiah I ; Ilomäki, Jenni ; Wood, Stephen J...
Journal of Epidemiology and Community Health.  76 (2022)  7 - p. 637-645 , 2022
Link: https://doi.org/10.1136/..
 
?
9

Impact of baseline polyneuropathy severity on patisiran tre..:

Quan, Dianna ; Obici, Laura ; Berk, John L....
Amyloid.  30 (2022)  1 - p. 49-58 , 2022
Link: https://doi.org/10.1080/..
 
?
10

Serum IgG and Autoantibody Lowering by the Anti-FcRn Monocl..:

Guptill, Jeff ; Antozzi, Carlo ; Bril, Vera...
Neurology.  98 (2022)  18_supplement - p. , 2022
Link: https://doi.org/10.1212/..
 
?
11

Serum Autoantibody Lowering by the Anti-FcRn Monoclonal Ant..:

Ramchandren, Sindhu ; Guptill, Jeff ; Antozzi, Carlo...
Neurology.  99 (2022)  23_Supplement_2 - p. , 2022
Link: https://doi.org/10.1212/..
 
?
12

Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibo..:

Nowak, Richard J. ; Coffey, Christopher S. ; Goldstein, Jonathan M....
Neurology.  98 (2022)  4 - p. , 2022
Link: https://doi.org/10.1212/..
 
?
13

Clinical and genetic profile of patients enrolled in the Tr..:

Dispenzieri, Angela ; Coelho, Teresa ; Conceição, Isabel...
Orphanet Journal of Rare Diseases, 1750-1172, 2022, 17:1,.  , 2022
Link: http://urn.kb.se/resolve..
 
?
14

Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibo..:

Nowak, Richard J ; Coffey, Christopher S ; Goldstein, Jonathan M...
qt3kc6g1jn.  , 2022
Link: https://escholarship.org..
 
?
15

Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibo..:

Nowak, Richard J ; Coffey, Christopher S ; Goldstein, Jonathan M...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793103/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
1-15